Thermally-Targeted Delivery of Medicaments Including Doxorubicin
Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including chemotherapeutic drugs.
Background
The present innovation generally relates to the field of targeted delivery systems for delivering therapeutic agents to tumors, in particular to tumor cells and tumor-associated cells. The invention further relates to methods of delivering a therapeutic agent to tumor cells and tumor-associated cells for the prevention and treatment of cancer by killing tumor cells and tumor-associated cells. Specifically, the delivery systems of the present innovation are capable of delivering an increased amount of therapeutics to tumor cells and tumor associated cells as compared to other delivery systems. In particular, the delivery systems of the present innovation are capable of accumulating a higher amount of therapeutic agent in tumor cells, or in cells that contribute to tumor cell viability ( e.g. vascular endothelial cells), and of leading to exposure of these cells to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present innovation also describes pharmaceutical compositions and tumor cells comprising the delivery systems of the present invention. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments.
Technology Overview
An aspect of the present innovation is a drug delivery compound and/or composition that targets a tumor site by applying local hyperthermia.
Another aspect of the present innovation is a drug delivery compound that is soluble under physiological conditions (TT,), which will allow preferential accumulation of the drug only at the targeted, locally heated diseased sites.
Another aspect of the present innovation is a drug delivery compound or composition for the selective delivery of a therapeutic/anticancer agent such as, for example, doxorubicin (Dox).
Benefits
A thermally responsive polypeptide carrier for anticancer agents such as, for example, the drug doxorubicin, which has the potential to be targeted to the tumor site by applying local hyperthermia.
Applications
The delivery of a therapeutic peptide or drug based agent is enhanced for the improved treatment of cancer.
Applications of the present innovation relates to combination therapies for treating cancer in a subject by administering to said subject a therapeutically or prophylactically effective amounts of one or more delivery systems and/or pharmaceutical compositions, sequentially or simultaneously, with surgery, standard and experimental chemotherapies, hormonal therapies, biological therapies, immunotherapies, radiation therapies, embolization, and/or chemoembolization therapies for the treatment or prevention of cancer.
Opportunity
Development partner
Commercial partner
Licensing
Seeking investment